Three years after IMT recurrence, disease remains under control.<h4>Conclusion</h4>This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.